ANJI

Serial Number 90843473
606

Registration Progress

Application Filed
Jul 22, 2021
Under Examination
Mar 7, 2023
Approved for Publication
Jan 10, 2023
Published for Opposition
Jan 10, 2023
Registered

Trademark Image

ANJI

Basic Information

Serial Number
90843473
Filing Date
July 22, 2021
Published for Opposition
January 10, 2023
Abandonment Date
April 8, 2024
Drawing Code
4

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Apr 8, 2024
Classes
005

Rights Holder

Anji Pharmaceuticals Inc.

03
Address
245 Main Street
Cambridge, MA 02142

Ownership History

Anji Pharmaceuticals Inc.

Original Applicant
03
Cambridge, MA

Anji Pharmaceuticals Inc.

Owner at Publication
03
Cambridge, MA

Legal Representation

Attorney
Nicole Kinsley, Esq.

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

32 events
Date Code Type Description Documents
Apr 8, 2024 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED Loading...
Apr 8, 2024 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Aug 9, 2023 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 7, 2023 EX1G S SOU EXTENSION 1 GRANTED Loading...
Aug 7, 2023 EXT1 S SOU EXTENSION 1 FILED Loading...
Aug 7, 2023 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Jun 30, 2023 EWAF I TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS Loading...
Jun 30, 2023 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jun 30, 2023 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Jun 30, 2023 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Mar 7, 2023 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jan 10, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Jan 10, 2023 PUBO A PUBLISHED FOR OPPOSITION Loading...
Dec 21, 2022 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Dec 8, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Dec 8, 2022 XAEC I EXAMINER'S AMENDMENT ENTERED Loading...
Dec 8, 2022 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Loading...
Dec 8, 2022 GNEA O EXAMINERS AMENDMENT E-MAILED Loading...
Dec 8, 2022 CNEA R EXAMINERS AMENDMENT -WRITTEN Loading...
Nov 25, 2022 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN Loading...
Nov 1, 2022 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY Loading...
Oct 20, 2022 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Oct 17, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Oct 17, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Oct 17, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 7, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 17, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Apr 17, 2022 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 17, 2022 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 15, 2022 DOCK D ASSIGNED TO EXAMINER Loading...
Sep 23, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jul 26, 2021 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
House mark for a full line of pharmaceutical preparations for human use; pharmaceutical preparations for human use for treatment and prevention of inflammatory, oncological, autoimmune, genetic, neurological, metabolic, infectious, hematological, musculo-skeletal, degenerative, cardiovascular, respiratory, gastrointestinal, endocrinological, dermatological, genitourinary, ophthalmological, hepatic, and nephrological diseases and conditions; pharmaceutical preparations for human use for treatment and prevention of pain; pharmaceutical preparations for human use for treatment and prevention of allergies

Classification

International Classes
005